Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study.
BACKGROUND Poor medication adherence is common among bipolar patients . METHOD We examined prospect i ve data from 2 cohorts of individuals from the Systematic Treatment Enhancement Program for Bipolar Disorder ( STEP-BD ) study ( 1999 - 2005 ) with bipolar disorder . Clinical and sociodemographic features associated with missing at least 25 % of doses of at least 1 medication were assessed using logistic regression , and a risk stratification model was developed and vali date d. RESULTS Of 3,640 subjects with 48,287 follow-up visits , 871 ( 24 % ) reported nonadherence on 20 % or more study visits . Clinical features significantly associated ( P < .05 ) with poor adherence included rapid cycling , suicide attempts , earlier onset of illness , and current anxiety or alcohol use disorder . Nonadherence during the first 3 months of follow-up was associated with less improvement in functioning at 12-month follow-up ( P < .03 ) . A risk stratification model using clinical predictors accurately classified 80.6 % of visits in an independent validation cohort . CONCLUSION Risk for poor medication adherence can be estimated and may be useful in targeting interventions
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .